Published Time: March 2026
Pages: 175
Format: PDF
Delivery Time: 2-3 Business Days
Report Price: $4490.00
By Type (Peptide Drugs, Anticoagulant Drugs, Peptide-Based Anticoagulant Drugs, Synthetic Peptide Drugs, Recombinant Peptide Drugs), By Route Of Administration (Oral, Injectable, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By Application (Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Other Applications), By End-users (Hospitals, Specialty Clinics, Homecare, Other End-users) – Market Size, Trends, Strategies, and Forecast to 2035
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Peptide and anticoagulant drugs are therapeutic agents where peptide drugs are short chains of amino acids that mimic natural biological molecules, and anticoagulant drugs prevent blood clotting by inhibiting clotting factors. Some anticoagulants, like hirudin and bivalirudin, are peptide-based, directly inhibiting thrombin to prevent thrombosis. These drugs are crucial in treating conditions such as deep vein thrombosis, pulmonary embolism, and stroke.
The main types of peptide and anticoagulant drugs are hormonal, antibiotic, ACE inhibitor, antifungal, and other types. Hormonal drugs, including peptide-based hormones like insulin and GLP-1 analogs, regulate hormone levels to treat conditions such as diabetes, while peptide and anticoagulant drugs provide targeted therapies for managing chronic diseases. These drugs can be administered through various routes, including oral, injectable, and other methods, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and others. Their applications span a wide range of medical fields, including infectious diseases, gynecology, cancer, diabetes, cardiology, osteoporosis, and others. End-users of these drugs include hospitals, specialty clinics, home care settings, and others.
The peptide and anticoagulant drugs market size has grown strongly in recent years. It will grow from $1.54 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to rising incidence of cardiovascular diseases, widespread use of anticoagulants in hospitals, clinical success of peptide therapeutics, growth in surgical procedures, expansion of thrombosis treatment guidelines.
The peptide and anticoagulant drugs market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to aging global population, increasing prevalence of blood clotting disorders, growing demand for safer anticoagulant therapies, expansion of peptide drug pipelines, rising adoption in outpatient care. Major trends in the forecast period include rising adoption of peptide-based therapeutics, increasing use of anticoagulants in cardiovascular care, growing demand for targeted thrombin inhibitors, expansion of injectable peptide drug applications, increased focus on preventing thrombotic disorders.
1) By Type: Peptide Drugs, Anticoagulant Drugs, Peptide-Based Anticoagulant Drugs, Synthetic Peptide Drugs, Recombinant Peptide Drugs
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By Application: Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Other Applications
5) By End-users: Hospitals, Specialty Clinics, Homecare, Other End-users
1) By Peptide Drugs: Therapeutic Peptides, Hormonal Peptides, Metabolic Peptides, Cardiovascular Peptides, Oncology Peptides
2) By Anticoagulant Drugs: Direct Thrombin Inhibitors, Factor Xa Inhibitors, Heparin And Heparin Derivatives, Vitamin K Antagonists
3) By Peptide-Based Anticoagulant Drugs: Hirudin And Hirudin Analogues, Bivalirudin, Other Peptide Thrombin Inhibitors
4) By Synthetic Peptide Drugs: Solid-Phase Synthesized Peptides, Long-Acting Synthetic Peptides, Modified Synthetic Peptides
5) By Recombinant Peptide Drugs: Recombinant Therapeutic Peptides, Recombinant Hormonal Peptides, Recombinant Metabolic Peptides
The rising prevalence of chronic diseases is expected to propel the growth of the peptide and anticoagulant drugs market going forward. Chronic diseases refer to long-term health conditions that persist over an extended period of time, often for years or even a lifetime. The rising prevalence of chronic diseases is driven by factors such as aging populations, unhealthy lifestyles, and increased incidence of risk factors such as obesity, hypertension, and diabetes. Peptide and anticoagulant drugs are used in chronic diseases to manage conditions such as cardiovascular diseases, thrombosis, and stroke by preventing blood clots and targeting specific disease pathways for improved patient outcomes. For instance, in May 2023, according to reports published by the Centers for Disease Control and Prevention, a US-based government organization, heart disease and cancer deaths totaled 695,547 in 2022. Therefore, the rising prevalence of chronic diseases is driving the growth of the peptide and anticoagulant drugs industry.
Major companies operating in the peptide and anticoagulant drugs market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., F. Hoffmann-La Roche Ltd, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Abbott Laboratories, Baxter International Inc., Viatris Inc., Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., Circle Pharma Inc., Teva Pharmaceutical Industries Ltd., Shionogi & Co. Ltd.
Major companies operating in the peptide and anticoagulant drugs market are focusing on advancements in anticoagulant therapies, such as oral anticoagulants, to enhance efficacy, improve patient compliance, and reduce the risk of bleeding complications. An oral anticoagulant is a medication taken by mouth to prevent blood clots by inhibiting clotting factors in the blood. For instance, in April 2024, Cadrenal Therapeutics Inc., a US-based pharmaceutical company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is designed to be a novel, reversible blood thinner aimed at reducing the risk of heart attacks, strokes, and mortality associated with blood clots in patients with rare cardiovascular conditions. The ODD applies specifically to the prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), ventricular assist devices (VADs), biventricular assist devices, and total artificial hearts.
In September 2023, Biosynth, a Switzerland-based provider of complex chemicals and biological materials, acquired Pepceuticals for an undisclosed amount. Biosynth's acquisition of Pepceuticals aims to expand its capabilities in the development and manufacturing of peptide-based therapeutics and biomaterials. This strategic move enhances Biosynth's position in the life sciences sector, allowing for a broader portfolio of advanced solutions for the pharmaceutical and biotechnology industries. Pepceuticals Ltd is a UK-based manufacturer of synthetic peptides.
North America was the largest region in the peptide and anticoagulant drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The peptide and anticoagulant drugs market consists of sales of peptide-based drugs and heparins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The peptide and anticoagulant drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the peptide and anticoagulant drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.
Author :Abhilash Pyata
